ArticleBMC cancer2025
Genetic alterations and aberrant hormonal pathways in thymic epithelial tumors.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPatients with thymic epithelial tumors (TETs) frequently show coexistence of various paraneoplastic syndromes, which severely affect their survival. Moreover, there is a lack of effective clinical treatment strategies for patients with unresectable metastatic and recurrent TETs.
methodsTo explore the genetic alterations that play a key role in the pathogenesis of TETs, we analyzed the whole-exome sequencing data from 24 patients diagnosed to have TETs at the First Affiliated Hospital of Nanjing Medical University.
resultsMutated genes in TETs were enriched in several hormone-associated pathways such as insulin secretion; Cushing syndrome; parathyroid hormone; and thyroid hormone, as well as multiple classical tumor-associated pathways, including cAMP, Notch, PI3K-Akt, and WNT signaling pathway. Patients with paraneoplastic syndromes (PNS) exhibited more pronounced alterations in hormone-related pathways. RHPN2 is the most frequently mutated gene in TETs. TETs with RHPN2 mutation showed greater upregulation of the hormone-related signaling pathways such as thyroid hormone and parathyroid hormone as well as a trend toward shorter survival of patients.
conclusionWe analyzed the possible role of hormones in TETs on several levels, explored potential links between hormones and other genetic mutations, and found that RHPN2 may be a potentially valuable gene.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.